Skip to main content

Table 1 Patients’ characteristics

From: Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy

Characteristics FIR (n = 49) UIR (n = 82) Total (n = 131) p value
  n. % n. % n. %  
Age
 Median (range) 74 (55–84) 74 (53–88) 74 (53–88) 0,39
  < 75 years 28 57,1 41 50,0 69 52,7 0,43
  ≥ 75 years 21 42,9 41 50,0 62 47,3
PSA at diagnosis
 Median (range) 9,6 (0,9–19,0) 8,5 (0,9–19,99) 9,0 (0,9–19,9) 0,72
  < 10 ng/mL 24 51,1 46 56,8 70 54,7 0,53
 10–19,9 ng/mL 23 48,9 35 43,2 58 45,3
Clinical T stage
 T1c 16 32,7 13 15,9 29 22,1 <0.001
 T2a 32 65,3 23 28,0 55 42,0
 T2b 1 2,0 27 32,9 28 21,4
 T2c 0 0 19 23,2 19 14,5
Biopsy Gleason score
 3 + 3 26 53,1 9 11,0 35 26,7 <0.001
 3 + 4 23 46,9 44 53,7 67 51,1
 4 + 3 0 0 29 35,4 29 22,1
PPBCs
  < 50 % 49 100 39 47,6 88 67,2 <0,001
  ≥ 50 % 0 0 43 52,4 43 32,8
IRFs
  < 2 49 100 23 28,0 72 55,0 <0,001
  ≥ 2 0 0 59 72,0 59 45,0
HT
 Antiandrogen 32 65,3 56 68,3 88 67,2 0,72
 LHRH analogue 17 34,7 26 31,7 43 32,8